Financial Data and Key Metrics Changes - The company ended 2025 with a strong cash position of approximately $713.4 million, with no debt [30] - Total GAAP operating expenses for Q4 2025 were $225 million, a decrease from $234.2 million in Q3 2025, primarily due to lower stock-based compensation expenses [30][31] - Non-GAAP operating expenses for Q4 2025 were $113.3 million, an increase from $103.4 million in Q3 2025, mainly driven by increased R&D expenses related to clinical trials [31] Business Line Data and Key Metrics Changes - The HARMONi-3 phase III trial for Ivonescimab has completed screening for the squamous cohort, with the last patient expected to be randomized shortly [8][10] - The company has announced a new phase III study, ILLUMINE, evaluating Ivonescimab in head and neck cancer, with initial enrollment expected to begin early next quarter [11][12] Market Data and Key Metrics Changes - Over 60,000 patients in China have received Ivonescimab based on two approved indications, with a third indication currently under review [16] - The total addressable market for Ivonescimab is estimated to exceed $100 billion globally, with potential improvements over current standards of care [27] Company Strategy and Development Direction - The company is focused on expanding its clinical development plan and preparing for commercialization, anticipating a decision from the FDA on its BLA by the end of the year [7][19] - The strategy includes accelerating enrollment in clinical trials and enhancing commercial readiness for potential launches [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the interim PFS analysis for HARMONi-3, which is expected in Q2 2026, and emphasized the importance of the positive data from previous trials [29][38] - The company is confident that the PFS benefits observed in trials will translate into overall survival benefits in the frontline population [74][77] Other Important Information - The company has initiated collaborations with Revolution Medicines and GSK to evaluate Ivonescimab in combination with novel therapies [14][23] - A total of 15 phase III trials are currently ongoing or have been announced, with a significant number of patients enrolled across various studies [15][17] Q&A Session Summary Question: What drove the decision to include the interim PFS analysis for HARMONi-3? - The decision was based on positive data from HARMONi-2 and HARMONi-6, allowing for earlier discussions with regulatory agencies [36][37] Question: Was there anything specific in HARMONi-3 that increased confidence for the interim analysis? - The decision was data-backed, influenced by the positive results from HARMONi-2 and HARMONi-6, rather than new information from HARMONi-3 [42][43] Question: What gives confidence that positive PFS data will translate to OS benefits? - The company highlighted the consistency of results across multiple trials and the importance of PFS in delaying the next line of therapy, which should translate to OS benefits [74][77]

Financial Data and Key Metrics Changes - The company ended 2025 with a strong cash position of approximately $713.4 million, with no debt [30] - Total GAAP operating expenses for Q4 2025 were $225 million, a decrease from $234.2 million in Q3 2025, primarily due to lower stock-based compensation expenses [30][31] - Non-GAAP operating expenses for Q4 2025 were $113.3 million, an increase from $103.4 million in Q3 2025, mainly driven by increased R&D expenses related to clinical trials [31] Business Line Data and Key Metrics Changes - The HARMONi-3 study for ivonesimab has completed screening for the squamous cohort, with the last patient expected to be randomized soon [8] - The company has announced an interim PFS analysis for the squamous cohort of HARMONi-3, planned for Q2 2026 [10][29] - The ILLUMINE study, a new Phase III trial in head and neck cancer, is expected to begin enrollment early next quarter [11] Market Data and Key Metrics Changes - Over 60,000 patients in China have received ivonesimab based on two approved indications, with a third indication currently under review [16] - The total addressable market for ivonesimab is estimated to exceed $100 billion globally, with significant potential in multiple tumor types [27] Company Strategy and Development Direction - The company is focused on expanding its clinical development plan and preparing for commercialization, anticipating a decision from the FDA on its BLA by the end of 2026 [7][19] - The strategy includes leveraging positive data from previous trials to accelerate discussions with regulatory agencies [36][55] - The company aims to expand its footprint in the oncology market, particularly in non-small cell lung cancer, by utilizing synergies across different patient populations [80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ivonesimab, citing positive data from previous trials and the need for effective treatments in oncology [19][27] - The company is preparing for a potential commercial launch in anticipation of FDA approval, ramping up commercial capabilities [32] - Management emphasized the importance of interim analyses to facilitate earlier discussions with regulatory bodies [36][55] Other Important Information - The company has initiated multiple collaborations, including with GSK and Revolution Medicines, to explore new treatment combinations [14][23] - A total of 15 Phase III trials are ongoing or have been announced, demonstrating the company's commitment to expanding its clinical research [17] Q&A Session Summary Question: What drove the decision to include the interim PFS analysis for HARMONi-3? - The decision was based on positive results from previous studies (HARMONi-2 and HARMONi-6) and the desire to accelerate timelines for regulatory discussions [36][37] Question: Was there anything specific in HARMONi-3 that increased confidence for the interim analysis? - The decision was data-backed, influenced by the positive outcomes from HARMONi-2 and HARMONi-6, rather than new information from HARMONi-3 [42][43] Question: What signals will be used to consider expanding into the U.S. for the head and neck study? - Enthusiasm from enrollment and feedback from the cooperative group, along with data from ongoing studies, will guide the decision [61][67]

Financial Data and Key Metrics Changes - The company ended 2025 with a strong cash position of approximately $713.4 million, with no debt [29] - Total GAAP operating expenses for Q4 2025 were $225 million, a decrease from $234.2 million in Q3 2025, primarily due to lower stock-based compensation expenses [30] - Non-GAAP operating expenses for Q4 2025 were $113.3 million, an increase from $103.4 million in Q3 2025, mainly driven by increased R&D expenses related to clinical trials [31] Business Line Data and Key Metrics Changes - The HARMONi-3 study for ivonesimab has completed screening for the squamous cohort, with the last patient expected to be randomized soon [7] - The company has announced an interim PFS analysis for the squamous cohort of HARMONi-3, planned for Q2 2026 [9] - The ILLUMINE study, evaluating ivonesimab in head and neck cancer, is set to begin enrollment early next quarter [10] Market Data and Key Metrics Changes - Over 60,000 patients in China have received ivonesimab based on two approved indications, with a third indication currently under review [14] - The total addressable market for ivonesimab is estimated to exceed $100 billion globally, with potential improvements over current standard of care [26] Company Strategy and Development Direction - The company is focused on expanding its clinical development plan and preparing for commercialization, anticipating a decision from the FDA on its BLA by the end of the year [6] - The strategy includes ramping up commercial capabilities in anticipation of potential launch and expanding into additional settings with multiple collaborations [20][21] - The company aims to leverage positive data from ongoing trials to accelerate discussions with regulatory agencies [56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ivonesimab based on positive data from previous trials, emphasizing the importance of bringing the treatment to patients as soon as possible [44] - The company is optimistic about the upcoming interim PFS analysis and believes it will facilitate earlier discussions with the FDA regarding the drug's approval [59] Other Important Information - The company has initiated 44 clinical trials since 2019, with over 4,000 patients enrolled globally [13] - The company has entered into collaborations with Revolution Medicines and GSK to evaluate ivonesimab in combination with novel therapies [21][22] Q&A Session All Questions and Answers Question: What drove the decision to include the interim PFS analysis for HARMONi-3? - The decision was based on positive results from HARMONi-2 and HARMONi-6, allowing for earlier discussions with regulatory agencies [36] Question: Was there anything specific in HARMONi-3 that increased confidence for the interim analysis? - The decision was data-backed, influenced by the positive interim readouts from HARMONi-2 and HARMONi-6 [42] Question: What gives confidence that positive PFS data will translate to OS benefits? - The company highlighted the consistency of results across multiple studies, with a strong correlation between PFS and OS benefits observed in similar trials [72] Question: How much of the commercial footprint for EGFR mutant non-small cell lung cancer will be usable for the broader squamous population? - The company indicated that there are significant synergies in the commercial footprint, as many physicians treat both populations [81]

Core Viewpoint - Akeso Inc. has received Orphan Drug Designation from the U.S. FDA for its monoclonal antibody ligufalimab (AK117) aimed at treating acute myeloid leukemia (AML) [1][2]. Company Overview - Akeso is a biopharmaceutical company focused on developing innovative biological medicines, with a robust pipeline of over 50 assets in various disease areas, including cancer and autoimmune diseases [15]. - The company utilizes an integrated R&D innovation system and has developed a comprehensive drug development platform [15]. Drug Development and Clinical Trials - Ligufalimab is currently in international clinical development for both hematologic malignancies and solid tumors, with completed patient enrollment in a Phase II study for higher-risk myelodysplastic syndromes [3][4]. - It is the first CD47 monoclonal antibody to enter Phase III trials for solid tumors, with ongoing studies for head and neck squamous cell carcinoma and pancreatic cancer [4]. Clinical Need and Market Opportunity - AML is the most common type of acute leukemia in adults, with limited treatment options for patients ineligible for intensive chemotherapy [5]. - Current treatments, such as venetoclax combined with azacitidine, show a high relapse rate, indicating a significant unmet clinical need [6]. Mechanism of Action - Ligufalimab targets CD47 on tumor cells, enhancing macrophage-mediated phagocytosis and inhibiting tumor growth, with improved safety and efficacy compared to other CD47-targeting agents [7]. Efficacy and Safety Profile - Clinical trials indicate that ligufalimab combined with azacitidine has a favorable safety profile, achieving a complete remission rate of 50% and a composite complete remission rate of 55% [9]. - A Phase II study is underway to further assess the safety and efficacy of ligufalimab in combination with venetoclax and azacitidine for AML patients [10].

Business Highlights - Akeso's commercial sales revenue in 2025H1 reached RMB 1.402 billion, a 49% year-on-year increase[16, 24] - The company has 13 Phase III/registrational trials of ivonescimab covering lung cancer and expanding to cold tumors[13] - The company has 10 phase III clinical studies of cadonilimab across lung cancer, gastric cancer, liver cancer and cervical cancer[13] - Penpulimab receives FDA approval in the United States[14] Pipeline Development - Three blockbuster new drug candidates entered clinical stage[19] - Six Phase III clinical trials reached the primary endpoint[20] - Ivonescimab's first global Phase III trial received positive results[84] - Manfidokimab (IL-4Rα) Reached Endpoints in the Registrational Phase III Trial for Atopic Dermatitis[116] Financial Performance - 1H 2025 Revenue reached RMB 1.412 billion, a 33.7% growth from 1H in 2024[16] - The company has cash and short-term financial assets of approximately RMB 7.14 billion[16] - Sales and Marketing expense as a percentage of sales decreased from 55% in 2024H1 to 48% in 2025 H1[136, 140]